EEA1 and triple-negative breast carcinoma: To determine the trafficking pathway followed by ECM components, we measured Matrigel colocalisation with an early endosomal marker, EEA1, and a late endosomal/lysosomal marker, LAMP2, in MDA-MB-231 triple-negative breast cancer cells.